1. Home
  2. MDGL vs BWA Comparison

MDGL vs BWA Comparison

Compare MDGL & BWA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDGL
  • BWA
  • Stock Information
  • Founded
  • MDGL 2011
  • BWA 1987
  • Country
  • MDGL United States
  • BWA United States
  • Employees
  • MDGL N/A
  • BWA N/A
  • Industry
  • MDGL Biotechnology: Pharmaceutical Preparations
  • BWA Auto Parts:O.E.M.
  • Sector
  • MDGL Health Care
  • BWA Consumer Discretionary
  • Exchange
  • MDGL Nasdaq
  • BWA Nasdaq
  • Market Cap
  • MDGL 7.1B
  • BWA 6.6B
  • IPO Year
  • MDGL N/A
  • BWA 1993
  • Fundamental
  • Price
  • MDGL $336.23
  • BWA $29.49
  • Analyst Decision
  • MDGL Buy
  • BWA Buy
  • Analyst Count
  • MDGL 14
  • BWA 15
  • Target Price
  • MDGL $351.67
  • BWA $40.46
  • AVG Volume (30 Days)
  • MDGL 357.1K
  • BWA 2.7M
  • Earning Date
  • MDGL 02-26-2025
  • BWA 02-06-2025
  • Dividend Yield
  • MDGL N/A
  • BWA 1.49%
  • EPS Growth
  • MDGL N/A
  • BWA N/A
  • EPS
  • MDGL N/A
  • BWA 1.50
  • Revenue
  • MDGL $76,813,000.00
  • BWA $14,086,000,000.00
  • Revenue This Year
  • MDGL N/A
  • BWA $3.34
  • Revenue Next Year
  • MDGL $195.95
  • BWA $5.27
  • P/E Ratio
  • MDGL N/A
  • BWA $18.09
  • Revenue Growth
  • MDGL N/A
  • BWA N/A
  • 52 Week Low
  • MDGL $189.00
  • BWA $28.65
  • 52 Week High
  • MDGL $368.29
  • BWA $38.23
  • Technical
  • Relative Strength Index (RSI)
  • MDGL 52.41
  • BWA 39.26
  • Support Level
  • MDGL $334.13
  • BWA $28.65
  • Resistance Level
  • MDGL $354.49
  • BWA $30.49
  • Average True Range (ATR)
  • MDGL 13.20
  • BWA 0.99
  • MACD
  • MDGL 0.16
  • BWA -0.02
  • Stochastic Oscillator
  • MDGL 43.12
  • BWA 19.40

About MDGL Madrigal Pharmaceuticals Inc.

Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.

About BWA BorgWarner Inc.

BorgWarner is a tier one supplier of turbo and thermal management technologies, drivetrain systems, powerdrive systems, and battery and charging systems mostly to automotive original equipment manufacturers. Its products aim to move a vehicle with as few electrons as possible, resulting in cleaner, cost-optimized, and more-efficient vehicles. Foundational products, the combustion vehicle business, contributes more than 80% to group revenue while BorgWarner transitions to becoming an electric vehicle-centric parts supplier (e-business). In 2023, 25% of the company's revenue was sourced from Volkswagen and Ford. Revenue is well diversified geographically, with approximately a third each generated in North America, Europe, and Asia.

Share on Social Networks: